Portage Biotech Inc. Sells 22,996 Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) major shareholder Portage Biotech Inc. sold 22,996 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $30.03, for a total value of $690,569.88. Following the transaction, the insider now owns 6,278,504 shares in the company, valued at approximately $188,543,475.12. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Portage Biotech Inc. also recently made the following trade(s):

  • On Tuesday, January 9th, Portage Biotech Inc. sold 84,881 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $30.06, for a total value of $2,551,522.86.
  • On Wednesday, January 3rd, Portage Biotech Inc. sold 35,650 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $28.61, for a total value of $1,019,946.50.

Biohaven Pharmaceutical Holding Co Ltd (NYSE BHVN) opened at $27.09 on Thursday. Biohaven Pharmaceutical Holding Co Ltd has a 52 week low of $17.00 and a 52 week high of $39.51. The stock has a market capitalization of $975.72 and a price-to-earnings ratio of -5.19.

Several institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc bought a new position in shares of Biohaven Pharmaceutical in the 3rd quarter valued at $119,000. Nationwide Fund Advisors bought a new position in shares of Biohaven Pharmaceutical in the 3rd quarter valued at $214,000. American International Group Inc. bought a new position in shares of Biohaven Pharmaceutical in the 3rd quarter valued at $251,000. State of Wisconsin Investment Board bought a new position in shares of Biohaven Pharmaceutical in the 3rd quarter valued at $262,000. Finally, Susquehanna International Group LLP bought a new position in shares of Biohaven Pharmaceutical in the 3rd quarter valued at $302,000. Institutional investors own 47.76% of the company’s stock.

A number of research firms have commented on BHVN. Needham & Company LLC lowered their price objective on Biohaven Pharmaceutical from $43.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday, October 3rd. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. BidaskClub lowered Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Thursday, October 5th. William Blair restated an “outperform” rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, October 3rd. Finally, Morgan Stanley restated an “overweight” rating and set a $38.00 price objective (down previously from $47.00) on shares of Biohaven Pharmaceutical in a research note on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. Biohaven Pharmaceutical has an average rating of “Buy” and a consensus target price of $36.14.

ILLEGAL ACTIVITY NOTICE: “Portage Biotech Inc. Sells 22,996 Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/11/portage-biotech-inc-sells-22996-shares-of-biohaven-pharmaceutical-holding-co-ltd-bhvn-stock.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply